Long-term self-management of anticoagulation therapy after mechanical heart valve replacement in outside trial conditions

Abstract

In this investigation, we hypothesize that quality of oral anticoagulation (OA) and long-term outcome after mechanical heart valve (MHV) replacement with self-management (Self-M) of OA is superior to conventional anticoagulation treatment (Conv-T), even in outside trial conditions. One hundred sixty patients (78.8% aortic valve replacements) were trained in international normalized ratio Self-M and 260 patients (86.2% aortic valve replacements) preferred Conv-T. Mean follow-up was 8.6±2.1 years, representing 3612 patient-years. During follow-up, 37.2% bleedings and 10.6% thromboembolic events were recorded in the Self-M group versus 39.6% bleedings (P=0.213) and 15.4% thromboembolic events (P=0.064) in the Conv-T group. Serious adverse events were significantly lower in the Self-M group [grade III bleeding events causing disability or death: 0 versus 4.6% (P=0.03); grade III thromboembolic events: 0.6 versus 5.0% (P=0.011)]. Patients with Self-M were significantly more satisfied with their OA management and their quality of life (P<0.001). Actuarial survival after 1, 5 and 10 years was 100, 99 and 97 with Self-M and 100, 95 and 81% with Conv-T, respectively (P<0.001). Univariate risk factors for mortality were age (P=0.008), type of operation (P=0.021) and conventional OA (P<0.001). In multivariate analysis, only conventional OA reached significance (P<0.001). We conclude that in a routine setting under outside trial conditions Self-M of OA improves long-term outcome and treatment quality.